sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics Reports Financial Position and Business Progress
Paris, France, July 23, 2024 - GenSight Biologics, a biopharma company focusing on gene therapies for retinal diseases, announced a cash position of €6.9 million as of June 30, 2024. The company reported sufficient working capital to meet obligations until the beginning of Q4 2024.
The company completed a successful capital increase in May 2024, raising €9.2 million. These funds, alongside renegotiation of state-guaranteed loans and convertible bonds, have bolstered their financial standing.
GenSight Biologics has started manufacturing the LUMEVOQ® drug product. This step is crucial for the resumption of its early access program in France by late Q3 2024. Over 100 vials could be available for patients following quality control tests.
The company is actively collaborating with the ANSM and the Quinze-Vingts Hospital in Paris to ensure the resumption of the early access program, which is eagerly awaited by patients.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.